More people are living 5 years after cancer diagnosis, new data shows

The American Cancer Society reports that five-year relative survival for all cancers has reached 70%, driven by gains in early detection, reduced tobacco use and improved therapies, with notable survival improvements for myeloma and liver and lung cancers. The ACS projects roughly 5,800 new cancer diagnoses per day in 2026 (over 2 million total) and more than 620,000 deaths, highlights rising incidence for several common cancers and persistent disparities among Native American and Black communities, and warns that federal research funding and insurance access threats could stall progress—key considerations for biotech, payers and healthcare policy exposure.

Analysis

Market structure: Rising 5-year survival (70%) shifts oncology from acute, once-off interventions toward chronic, recurring care (maintenance immunotherapies, oral targeted agents, surveillance imaging and liquid biopsies). Winners: diagnostics (NGS, liquid biopsy), CROs and chronic oncology drugmakers that monetize long-duration treatment; losers: high-intensity inpatient oncology services and one-time high-mortality therapeutics. Expect pricing pressure from payers over chronic high-cost biologics but enlarged addressable market (incidence >2M/year) supports volume-led revenue growth over 3–5 years.

Risk assessment: Key tail risks include sustained federal research-funding cuts or major reimbursement downgrades (CMS/NCD changes) that could shave 20–40% off early-stage diagnostic revenue projections short-term. Immediate (days–weeks): policy headlines and CMS draft rulings; short-term (3–12 months): trial readouts, FDA approvals, appropriations cycle; long-term (2–5 years): payer pushback, biosimilar penetration and shifting screening guidelines. Hidden dependencies: survival gains depend on screening uptake and insurance access — disparities imply uneven TAM realization across regions.

Trade implications: Direct plays favor ILMN and GH (diagnostics), IQV (CRO exposure to growing trial volume), MRK/BMY (immune-oncology backbooks). Pair opportunity: long diagnostics/CRO exposure vs short hospital inpatient names (HCA) and selective payers if CMS reimbursement weakens. Use defined-risk options around known catalysts (FDA PDUFA, CMS decisions) and size positions 1–3% of AUM with 6–12 month horizons.

Contrarian angles: Consensus may underweight diagnostics because survival improvement is seen as reducing need for aggressive therapies — actually surveillance and molecular monitoring will expand per-patient revenue by 20–50% over years. Funding-threat narrative could create short-term selloffs in quality names; these are asymmetric buy opportunities if CMS/FDA noise doesn’t translate to structural reimbursement cuts. Monitor tobacco/policy shifts and screening guideline updates which can rapidly re-rate names.

Key Decisions for Investors

• Establish a 2.5% long position in Illumina (ILMN) over the next 4 weeks, add up to +1.5% on pullbacks >8%, target 12–18% total return in 6–12 months driven by sequencing-as-surveillance demand; stop-loss at -12%.
• Initiate a 2% long position in Guardant Health (GH) via a 3‑month 1.2x notional call spread (buy 3‑6 month ATM call, sell higher strike) ahead of next quarterly results/PgDx reimbursement updates; risk defined, upside from liquid biopsy adoption within 3–9 months.
• Enter a pair trade: long IQV (IQV) 2% vs short HCA Healthcare (HCA) 2% (equal dollar). Rationale: outsourced trials and diagnostics growth vs declining late-stage inpatient oncology volume; rebalance after 6 months or on +/-15% move.
• Buy a 6–9 month MRK (Merck) call spread sized 1% of AUM ahead of key trial readouts; this captures upside from continued I/O uptake while limiting premium paid—monitor FDA/PDUFA calendar and CMS NCD announcements in the next 30–90 days as exit/cut triggers.